Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel Free TROV Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Cardiff Oncology (TROV) Competitors

Cardiff Oncology logo
Compare

TROV vs. IZTC, ALVR, FNCH, NKGN, and ZIVO

Should you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Invizyne Technologies (IZTC), AlloVir (ALVR), Finch Therapeutics Group (FNCH), NKGen Biotech (NKGN), and ZIVO Bioscience (ZIVO). These companies are all part of the "medical" sector.

How does Cardiff Oncology compare to Invizyne Technologies?

Invizyne Technologies (NASDAQ:IZTC) and Cardiff Oncology (NASDAQ:TROV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Invizyne Technologies has higher earnings, but lower revenue than Cardiff Oncology.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Invizyne TechnologiesN/AN/AN/AN/AN/A
Cardiff Oncology$250K68.71-$16.41M-$2.80N/A

10.0% of Cardiff Oncology shares are held by institutional investors. 0.6% of Cardiff Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Invizyne Technologies has a net margin of 0.00% compared to Cardiff Oncology's net margin of -3,688.31%. Invizyne Technologies' return on equity of 0.00% beat Cardiff Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Invizyne TechnologiesN/A N/A N/A
Cardiff Oncology -3,688.31%-202.00%-122.92%

In the previous week, Invizyne Technologies had 1 more articles in the media than Cardiff Oncology. MarketBeat recorded 1 mentions for Invizyne Technologies and 0 mentions for Cardiff Oncology. Invizyne Technologies' average media sentiment score of 0.00 equaled Cardiff Oncology'saverage media sentiment score.

Company Overall Sentiment
Invizyne Technologies Neutral
Cardiff Oncology Neutral

Summary

Invizyne Technologies beats Cardiff Oncology on 4 of the 7 factors compared between the two stocks.

How does Cardiff Oncology compare to AlloVir?

AlloVir (NASDAQ:ALVR) and Cardiff Oncology (NASDAQ:TROV) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

66.1% of AlloVir shares are held by institutional investors. Comparatively, 10.0% of Cardiff Oncology shares are held by institutional investors. 32.1% of AlloVir shares are held by company insiders. Comparatively, 0.6% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

AlloVir has a net margin of 0.00% compared to Cardiff Oncology's net margin of -3,688.31%. AlloVir's return on equity of -71.03% beat Cardiff Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
AlloVirN/A -71.03% -61.27%
Cardiff Oncology -3,688.31%-202.00%-122.92%

AlloVir has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.

In the previous week, AlloVir's average media sentiment score of 0.00 equaled Cardiff Oncology'saverage media sentiment score.

Company Overall Sentiment
AlloVir Neutral
Cardiff Oncology Neutral

Cardiff Oncology has higher revenue and earnings than AlloVir. Cardiff Oncology is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AlloVirN/AN/A-$190.42M-$20.23N/A
Cardiff Oncology$250K68.71-$16.41M-$2.80N/A

Summary

AlloVir beats Cardiff Oncology on 6 of the 10 factors compared between the two stocks.

How does Cardiff Oncology compare to Finch Therapeutics Group?

Finch Therapeutics Group (NASDAQ:FNCH) and Cardiff Oncology (NASDAQ:TROV) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Finch Therapeutics Group has a net margin of 0.00% compared to Cardiff Oncology's net margin of -3,688.31%. Finch Therapeutics Group's return on equity of -69.14% beat Cardiff Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Finch Therapeutics GroupN/A -69.14% -26.92%
Cardiff Oncology -3,688.31%-202.00%-122.92%

Cardiff Oncology has higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Finch Therapeutics GroupN/AN/A-$74.75M-$8.82N/A
Cardiff Oncology$250K68.71-$16.41M-$2.80N/A

21.8% of Finch Therapeutics Group shares are held by institutional investors. Comparatively, 10.0% of Cardiff Oncology shares are held by institutional investors. 44.9% of Finch Therapeutics Group shares are held by company insiders. Comparatively, 0.6% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Finch Therapeutics Group's average media sentiment score of 0.00 equaled Cardiff Oncology'saverage media sentiment score.

Company Overall Sentiment
Finch Therapeutics Group Neutral
Cardiff Oncology Neutral

Finch Therapeutics Group has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.

Summary

Finch Therapeutics Group beats Cardiff Oncology on 6 of the 10 factors compared between the two stocks.

How does Cardiff Oncology compare to NKGen Biotech?

NKGen Biotech (NYSE:NKGN) and Cardiff Oncology (NASDAQ:TROV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

NKGen Biotech has a net margin of 0.00% compared to Cardiff Oncology's net margin of -3,688.31%. NKGen Biotech's return on equity of 0.00% beat Cardiff Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
NKGen BiotechN/A N/A -479.36%
Cardiff Oncology -3,688.31%-202.00%-122.92%

Cardiff Oncology has higher revenue and earnings than NKGen Biotech. Cardiff Oncology is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NKGen BiotechN/AN/A-$82.94M-$1.51N/A
Cardiff Oncology$250K68.71-$16.41M-$2.80N/A

76.2% of NKGen Biotech shares are owned by institutional investors. Comparatively, 10.0% of Cardiff Oncology shares are owned by institutional investors. 10.4% of NKGen Biotech shares are owned by company insiders. Comparatively, 0.6% of Cardiff Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, NKGen Biotech's average media sentiment score of 0.00 equaled Cardiff Oncology'saverage media sentiment score.

Company Overall Sentiment
NKGen Biotech Neutral
Cardiff Oncology Neutral

NKGen Biotech has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500.

Summary

NKGen Biotech beats Cardiff Oncology on 6 of the 10 factors compared between the two stocks.

How does Cardiff Oncology compare to ZIVO Bioscience?

ZIVO Bioscience (NASDAQ:ZIVO) and Cardiff Oncology (NASDAQ:TROV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

12.8% of ZIVO Bioscience shares are held by institutional investors. Comparatively, 10.0% of Cardiff Oncology shares are held by institutional investors. 48.9% of ZIVO Bioscience shares are held by company insiders. Comparatively, 0.6% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

ZIVO Bioscience has higher earnings, but lower revenue than Cardiff Oncology. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ZIVO Bioscience$15.85K1,073.09-$7.78M-$2.18N/A
Cardiff Oncology$250K68.71-$16.41M-$2.80N/A

In the previous week, ZIVO Bioscience's average media sentiment score of 0.00 equaled Cardiff Oncology'saverage media sentiment score.

Company Overall Sentiment
ZIVO Bioscience Neutral
Cardiff Oncology Neutral

ZIVO Bioscience has a beta of 0.04, suggesting that its share price is 96% less volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.

ZIVO Bioscience has a net margin of 0.00% compared to Cardiff Oncology's net margin of -3,688.31%. ZIVO Bioscience's return on equity of 0.00% beat Cardiff Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
ZIVO BioscienceN/A N/A -2,240.92%
Cardiff Oncology -3,688.31%-202.00%-122.92%

Summary

ZIVO Bioscience beats Cardiff Oncology on 7 of the 11 factors compared between the two stocks.

Get Cardiff Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TROV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TROV vs. The Competition

Export
MetricCardiff OncologyBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ Exchange
Market Cap$17.18M$329.01M$6.25B$11.77B
Dividend YieldN/AN/A2.74%5.26%
P/E Ratio-0.51N/A29.2527.07
Price / Sales68.71189.48504.6873.47
Price / CashN/A22.4443.3053.90
Price / Book1.664.739.676.69
Net Income-$16.41M-$132.96M$3.55B$332.64M

Cardiff Oncology Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TROV
Cardiff Oncology
N/A$1.56
flat		N/AN/A$17.18M$250KN/AN/A
IZTC
Invizyne Technologies
N/A$10.50
+0.2%		N/AN/A$65.65MN/AN/A29
ALVR
AlloVir
N/A$6.33
+0.8%		N/AN/A$31.92MN/AN/A110
FNCH
Finch Therapeutics Group
N/A$8.27
-1.8%		N/AN/A$13.28MN/AN/A190
NKGN
NKGen Biotech
N/A$0.06
flat		N/AN/A$7.84MN/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TROV) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel